Shane R Stecklein
Overview
Explore the profile of Shane R Stecklein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
488
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin M, Yoder R, Salgado R, Del Monte-Millan M, Alvarez E, Echavarria I, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2160-2169.
PMID: 38466643
Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs...
2.
Sharma P, Stecklein S, Yoder R, Staley J, Schwensen K, ODea A, et al.
JAMA Oncol
. 2023 Nov;
10(2):227-235.
PMID: 37991778
Importance: Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy of anthracycline-free chemoimmunotherapy in TNBC has not...
3.
Stecklein S, Barlow W, Pusztai L, Timms K, Kennedy R, Logan G, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300197.
PMID: 37972336
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease. We previously showed that homologous recombination deficiency (HRD) and the DNA damage immune response (DDIR) signature are prognostic in TNBC. We...
4.
Machiels M, Oulkadi R, Tramm T, Stecklein S, Somaiah N, De Caluwe A, et al.
Breast
. 2023 Jul;
71:13-21.
PMID: 37437386
Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and...
5.
Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D, et al.
JAMA Oncol
. 2023 Jul;
9(8):1083-1089.
PMID: 37410451
Importance: Little is known about regional nodal irradiation (RNI) practice patterns or rates of locoregional recurrence (LRR) with and without RNI in patients with limited nodal disease and favorable biology...
6.
Stecklein S, Kimler B, Yoder R, Schwensen K, Staley J, Khan Q, et al.
NPJ Breast Cancer
. 2023 Mar;
9(1):10.
PMID: 36878909
Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant...
7.
Subham S, Jeppson J, Worcester C, Schatmeyer B, Zhao J, Madan R, et al.
Breast Cancer Res Treat
. 2022 Nov;
197(1):57-69.
PMID: 36318382
Purpose: There is currently no curative treatment for patients diagnosed with triple-negative breast cancer brain metastases (TNBC-BM). CAR T cells hold potential for curative treatment given they retain the cytolytic...
8.
Yoder R, Kimler B, Staley J, Schwensen K, Wang Y, Finke K, et al.
NPJ Breast Cancer
. 2022 Jul;
8(1):80.
PMID: 35817765
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression <1% and absence of HER2 amplification/overexpression. HER2-negative breast cancer with low ER/PR expression...
9.
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation
Chapman B, Liu D, Shen Y, Olamigoke O, Lakomy D, Gutierrez Barrera A, et al.
Int J Radiat Oncol Biol Phys
. 2021 Oct;
112(2):426-436.
PMID: 34610390
Purpose: BRCA1/2 pathogenic variant (PV) mutations confer radiation sensitivity preclinically, but there are limited data regarding breast cancer outcomes after radiation therapy (RT) among patients with documented BRCA1/2 PV mutations...
10.
Chapman B, Liu D, Shen Y, Olamigoke O, Lakomy D, Gutierrez Barrera A, et al.
Int J Radiat Oncol Biol Phys
. 2021 Sep;
112(2):437-444.
PMID: 34582940
Purpose: Multigene panel testing has increased the detection of germline mutations in patients with breast cancer. The implications of using radiation therapy (RT) to treat patients with pathogenic variant (PV)...